CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View

Charles River Laboratories International (CRL) reported strong second-quarter 2025 results, with adjusted EPS of $3.12, an 11.4% year-over-year increase that beat estimates by 24.8%, and revenues of $1.03 billion, surpassing expectations by 5%. This performance, attributed to growth in its Research Models and Services (RMS) and Manufacturing Solutions segments and signs of biopharma demand stabilization, propelled CRL shares up 9.3% pre-market and led the company to raise its full-year 2025 EPS and revenue guidance, despite a contraction in its adjusted operating margin.

Analysis

Charles River Laboratories (CRL) delivered a strong second-quarter 2025 performance, primarily characterized by a significant earnings beat and an upgraded full-year outlook. The company reported an adjusted EPS of $3.12, an 11.4% year-over-year increase that surpassed consensus estimates by a notable 24.8%. While revenues of $1.03 billion also beat forecasts by 5%, the top line was nearly flat with just 0.6% reported growth and a 0.5% organic decline, indicating a mixed underlying performance. This divergence was evident at the segment level, where organic growth in Research Models and Services (+2.3%) and Manufacturing Solutions (+2.9%) was offset by a 2.4% organic revenue decline in the company's largest segment, Discovery and Safety Assessment (DSA). A key point of concern is the significant margin pressure; despite a slight gross margin expansion, a 12.8% rise in SG&A expenses led to a 10% decline in adjusted operating profit and a 189 basis point contraction in the adjusted operating margin to 16%. Nevertheless, the market reacted positively, with shares rising 9.3% pre-market, driven by the company raising its full-year 2025 adjusted EPS guidance to a range of $9.90-$10.30, well above its prior forecast and analyst consensus, citing signs of stabilization in biopharma demand.

Key Decisions for Investors

• Investors should weigh the bullish signal of a significantly raised full-year EPS guidance against the fundamental headwinds of a 189 bps contraction in operating margin and an organic revenue decline in the core DSA segment.
• Given the stock's 9.3% pre-market jump, it is crucial to assess whether the improved outlook is now fully priced in, or if the underlying profitability issues present a medium-term risk.
• Monitor future performance for a turnaround in the DSA segment's organic growth and evidence that management can control operating expenses to reverse the trend of margin erosion.